Research Center for the Characterization and Safe Use of Natural Products, University of Milan, Milan 20129, Italy.
Published: May 2007
AI Article Synopsis
Article Abstract
This work describes a sensitive high-performance liquid chromatography (HPLC) method for the quantification of aloesin and aloeresin A in alcoholic beverages containing aloe as a flavoring agent. The compounds were prepared from Aloe ferox juice. Sephadex LH20 and ion-exchange resin AG1X2 column chromatography were used for aloesin. Aloeresin A was obtained by Sephadex LH20 and silica gel column chromatography followed by purification on Discovery DSC-18 solid-phase extraction tubes. A 98 mg amount of aloesin (>99% purity) and 34 mg of aloeresin A (>98% purity) were recovered from 2.5 g of aloe juice. The HPLC method was validated, and intra- and interday performances were established. In-house validation was carried out by analyzing samples of beverages with and without aloe as a flavoring agent.
Ethnopharmacological Relevance: Aloe barbadensis Mill. (Aloe vera), is a homology of medicine and food plant, widely applied in functional food, cosmetics, and medicine. Aloe vera whole leaf extract, one of the most popular traditional Chinese medicines (TCMs), is mainly used in China to treat functional constipation.
An integrated strategy was developed for the systematic chemical fingerprint and chemometrics analysis for the quality assessment of Aloe vera (L.) Burm. f.
skin (AVS) is a major by-product of Aloe processing plants all over the world. In this study, response surface methodology was used to optimize microwave-assisted extraction (MAE) of bioactive compounds from AVS. The influence of extraction parameters, such as ethanol concentration (%Et), extraction temperature (T), time (t) and solvent volume (V), on extraction yield (Y), total phenolic content (TPC), antioxidant activity (DPPH and FRAP methods) and aloin content, was studied.
In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will arise from new SARS-CoV-2 variants. The main protease of SARS-CoV-2 (M) is an attractive drug target due to the clinical success of protease inhibitors against other viruses, such as HIV and HCV.
